- Home
- IFN vs CATX Comparison
IFN vs CATX Comparison
Compare IFN & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IFN | CATX |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.7M | 414.0M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IFN | CATX |
|---|---|---|
| Price | $11.61 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 154.1K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $1.96 |
| 52 Week High | $16.18 | $6.16 |
Technical Indicators
Market Signals| Indicator | IFN | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 38.92 |
| Support Level | $11.40 | $2.88 |
| Resistance Level | $11.79 | $4.27 |
| Average True Range (ATR) | 0.15 | 0.25 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 46.07 | 11.86 |
Price Performance
Historical ComparisonAbout IFN India Fund Inc. (The)
India Fund Inc is a non-diversified closed-end management investment company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.